Sinopharm (01099.HK) announced the performance of its subsidiary China National Accord Medicines Corporation (000028.SZ) for the first nine months, achieving a total operating income of 56.466 billion RMB, a slight decrease of 0.2% year-on-year. The attributable net profit to shareholders was 1.066 billion yuan, a decrease of 10.4%, with an earnings per share of 1.91 yuan.
國藥(01099.HK)附屬國藥一致首九月賺10.66億人民幣 倒退10.4%
china national accord medicines corporation (01099.HK) earned 1.066 billion RMB in the first nine months, a decrease of 10.4%.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated